Dx&Vx Announces ‘AI to the BIO’ Strategy... Strengthening Collaboration for Digital Healthcare Pipeline

Dx&Vx, a company specializing in diagnostics and vaccine development, announced on the 12th that it will actively pursue an ‘AI to the BIO’ strategy to develop future medical technologies and drive bio innovation through the use of AI technology.

‘AI to the BIO’ is a strategic initiative to internalize Dx&Vx’s assets through AI, Data, and Cloud. In addition to the ongoing infrastructure projects with Google Cloud and LG CNS, it includes expanding alliances through collaborations with various medical, IT, and bio companies.

First, based on its in-house diagnostic and vaccine development technologies, the company plans to integrate bio big data projects, patient classification systems, digital medical device management systems, telemedicine relay platforms, and digital therapeutics (DTx) through AI to grow into a Healthcare 4.0 company.

Subsequently, beyond applying AI to discover new drug candidates and preclinical trials, Dx&Vx aims to shorten patient enrollment periods in clinical trials through key initiatives enabling data-driven decision-making. By utilizing machine learning to analyze larger volumes of data, the company will continuously expand the scope of AI applications to support data-based decisions.

The future medical technology that Dx&Vx seeks to achieve through this is to structure bio big data and data-ize patient classification systems for infectious disease response or future quarantine systems. By connecting this with advanced medical institutions where medical data has high utilization value, it will be possible to develop new candidate substances, collect information, and create integrated models based on bioinformatics and IT technologies.

This is expected to dramatically improve the efficiency of processes required for new drug development. Although R&D expenditure is increasing annually, clinical development success rates are declining each year, making the enhancement of such technologies a significant factor in pharmaceutical companies’ competitiveness. Global big pharma companies are already heavily investing AI in new drug development.

By linking with the telemedicine relay platform currently being prepared for launch, the company plans to introduce services targeting patients in domestic emergency medical vulnerable areas and vulnerable time zones, and expand the scope to public welfare fields such as ‘chronic disease follow-up prescriptions’ and ‘infectious diseases requiring monitoring.’ Through these digital innovation technologies, Dx&Vx aims to build various partnerships and collaborations to provide effective solutions across the entire medical system, from disease diagnosis to patient risk factor detection and treatment.

A company representative stated, “AI and digital technologies have already become core elements in the future medical technology field within the pharmaceutical/bio sector, and the integration of AI and digital technologies has been steadily progressing. We will collaborate not only with the IT companies we are currently working with but also with various Bio-AI companies.”